Specialist managers see more shorting activity

James Fiore, primary manager of the Life Science Group Partners sector hedge fund, says the biotech and pharmaceutical-focused fund is presently 'predominantly in biotechnology' as the industry has had 'its worst bear market ever and is over 45% down for the year.'

Fiore says: 'Biotech is dominated in the US by individual investors and they're very skittish at the moment, so finding value in the sector is like shooting fish in a barrel.' He adds that a lot of biotechs are trading at levels below

To continue reading...

You must be signed in to use this feature.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: